According to the director of the institute, Dimas Covas, the drug will be applied to immunosuppressed patients who are severely ill
A National Health Surveillance Agency (Anvisa) authorized, this Wednesday, the 25th, the accomplishment of clinical tests of the anti-virus virus made with plasma of horses that has been developed by the Butantan Institute. The new stage now allows testing in humans. The approval request was made earlier this month, but, according to the agency, a few weeks after the request, Anvisa collected data that were pending.
The director of Butantan, Dimas Covas, said that the drug will be applied to immunosuppressed people and those with severe conditions of the disease. He stated that the serum works as a vaccine and explained how it acts in the body. “When you inject the serum, it is loaded with antibodies. These antibodies are there to fight the virus. You quickly clear the virus, you remove the virus from circulation and this allows the disease not to evolve, ”he said.
To produce the serum, plasma is taken from the horse’s blood and then taken to Butantan, where the antibodies are separated from this plasma and transformed into a soro anti-covid. The goal is to alleviate the symptoms of the disease. However, for the studies to begin, effectively, the institution must provide additional information. According to a note from the Butantan Institute, human testing is expected to begin in the next few days.
* With information from reporter Camila Yunes